Celldex Therapeutics (CLDX)

Company Profile

celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im

Company profile

Ticker

CLDX

Exchange

NASDAQ

Website

www.celldex.com/

CEO

Anthony Marucci

Incorporated

Delaware

Location

New Jersey

Fiscal year end

Dec 31

Sector

Manufacturing > Biological Product (except Diagnostic) Manufacturing

Industry (SIC)

In Vitro & In Vivo Diagnostic Substances

Ortho Clinical Diagnostics • QuidelOrtho • Idexx Laboratories • Myriad Genetics • Neogen • Lantheus • Meridian Bioscience • Lucira Health • Heska Corp. • Intellia Therapeutics ...

Former names

AVANT IMMUNOTHERAPEUTICS INC, T CELL SCIENCES INC

SEC CIK

0000744218

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Celldex Therapeutics Switzerland GmbH ...

IRS number

133191702

CLDX stock data

1M 1Y 5Y

Latest filings (excl ownership)

View all

8-K

Celldex Therapeutics Announces Proposed Public Offering of Common Stock

8 Nov 23

424B5

Prospectus supplement for primary offering

8 Nov 23

424B5

Prospectus supplement for primary offering

Automatic shelf registration

2 Nov 23

Celldex Reports Third Quarter 2023 Financial Results and Provides Corporate Update

8 Aug 23

Celldex Reports Second Quarter 2023 Financial Results and Provides Corporate Update

8 Aug 23

S-8

Registration of securities for employees

21 Jun 23

Transcripts

View all

CLDX

Earnings call transcript

2021 Q4

1 Mar 22

CLDX

Earnings call transcript

2020 Q2

6 Aug 20

CLDX

Earnings call transcript

2019 Q2

8 Aug 19

CLDX

Earnings call transcript

2018 Q4

7 Mar 19

CLDX

Earnings call transcript

2018 Q2

8 Aug 18

CLDX

Earnings call transcript

2017 Q3

7 Mar 18

Latest ownership filings

View all

SC 13G

Point72 Asset Management, L.P.

Financial summary

Financial statements Chart CLDX financial data

Quarter (USD)	Sep 23	Jun 23	Mar 23	Dec 22
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 22	Dec 21	Dec 20	Dec 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	21.13 mm	21.13 mm	21.13 mm	21.13 mm	21.13 mm	21.13 mm
Cash burn (monthly)	2.36 mm	(no burn)	13.75 mm	11.23 mm	6.33 mm	8.04 mm
Cash used (since last report)	5.45 mm	n/a	31.69 mm	25.90 mm	14.59 mm	18.54 mm
Cash remaining	15.69 mm	n/a	-10.56 mm	-4.76 mm	6.54 mm	2.59 mm
Runway (months of cash)	6.6	n/a	-0.8	-0.4	1.0	0.3

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Institutional ownership, Q3 2023

CLDX institutional ownership history Ownership history

13F holders	Current	Prev Q	Change
Total holders	143	149	-4.0%
Opened positions	17	18	-5.6%
Closed positions	23	28	-17.9%
Increased positions	60	61	-1.6%
Reduced positions	42	44	-4.5%

13F shares	Current	Prev Q	Change
Total value	1.38 tn	1.70 tn	-18.7%
Total shares	50.54 mm	50.37 mm	+0.3%
Total puts	488.67 k	120.20 k	+306.5%
Total calls	565.30 k	106.60 k	+430.3%
Total put/call ratio	0.9	1.1	-23.3%

Largest owners	Shares	Value	Change
FMR	7.09 mm	$195.09 bn	+0.0%
Wellington Management	5.43 mm	$149.48 bn	+5.9%
RTW Investments	3.46 mm	$95.31 bn	0.0%
BLK Blackrock	3.25 mm	$89.49 bn	+0.9%
Kynam Capital Management	3.20 mm	$88.06 bn	+23.1%
Vanguard	2.62 mm	$72.06 bn	+0.8%
Polar Capital	2.43 mm	$66.78 bn	+0.4%
STT State Street	2.29 mm	$63.10 bn	-15.9%
BLVGF Bellevue	1.90 mm	$52.29 bn	+5.6%
Pictet Asset Management Holding	1.85 mm	$50.94 bn	NEW

Largest transactions	Shares	Bought/sold	Change
Pictet Asset Management Holding	1.85 mm	+1.85 mm	NEW
Pictet Asset Management	0.00	-1.79 mm	EXIT
Jennison Associates	26.89 k	-1.30 mm	-98.0%
Kynam Capital Management	3.20 mm	+600.00 k	+23.1%
STT State Street	2.29 mm	-434.46 k	-15.9%
MS Morgan Stanley	523.70 k	+385.92 k	+280.1%
Wellington Management	5.43 mm	+300.41 k	+5.9%
Marshall Wace	538.32 k	+248.80 k	+85.9%
Candriam Luxembourg S.C.A.	322.51 k	-228.00 k	-41.4%
Sofinnova Investments	424.26 k	+226.50 k	+114.5%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Recent insider trades

CLDX insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
15 Jun 23	Shoos Karen L.	NQSO Common Stock	Grant	Acquire A	No	No	36.87	11,300	416.63 k	11,300
15 Jun 23	Cohen Cheryl	NQSO Common Stock	Grant	Acquire A	No	No	36.87	11,300	416.63 k	11,300
15 Jun 23	Marino James J	NQSO Common Stock	Grant	Acquire A	No	No	36.87	11,300	416.63 k	11,300
15 Jun 23	Conrad Herbert J	NQSO Common Stock	Grant	Acquire A	No	No	36.87	11,300	416.63 k	11,300
15 Jun 23	Neil Garry Arthur	NQSO Common Stock	Grant	Acquire A	No	No	36.87	11,300	416.63 k	11,300